Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Chemokine Therapeutics has completed enrollment of study subjects and administration of its investigational immune recovery drug CTCE-0214 in a phase I clinical trial.
Subscribe to our email newsletter
CTCE-0214 is a stable small peptide agonist of stromal cell-derived factor-1 (SDF-1), a key signaling molecule in the proliferation, homing, engraftment and expansion of hematopoietic stem cells and white blood cells. SDF-1 is also believed to work as a traffic controller for infection-fighting white blood cells and progenitor cell migration, providing an essential function to combat immunosuppression.
CTCE-0214, based on Chemokine’s preclinical research, mimics the activity of the natural chemokine SDF-1 by increasing the level of white blood cells, bleeding prevention cells and stem cells in the blood.
CTCE-0214 has the potential to restore a cancer patient’s immune system and blood cells between cycles of chemotherapy. In this clinical scenario, patients might be able to receive aggressive chemotherapy without delay by restoring infection-fighting white blood cells and increasing platelet counts to protect patients from bleeding.
The primary objective of the current phase I study is to evaluate the safety, pharmacodynamics and pharmacokinetic profile of CTCE-0214.
Chemokine Therapeutics expects the results of the study to be made available in Q2 2005, at which time the company will provide an update on the future clinical development of CTCE-0214.